EUCTR2004-001376-39-DE进行中（未招募）不适用
ong-term efficacy and safety evaluation of asenapine (10-20 mg/day) in subjects with schizophrenia or schizoaffective disorder, in a multicenter trial using olanzapine (10-20 mg/day) as a control. - N/A
V Organon0 个研究点目标入组 400 人开始时间: 2004年10月15日最近更新:
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 400
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •To be considered for inclusion into this trial subjects must have completed the ACTAMESA study and provide written informed consent (or verbal witnessed informed consent for illiterate subjects in South-Africa) after the scope and nature of the extension study have been explained to them.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Subjects will be excluded from further consideration if they do not fulfill the inclusion criteria, or if they either suffer from a medical condition or require concomitant treatment that will obscure trial results or will put the patient at increased risk for treatment failure or unacceptable adverse events. It is left to the discretion of the investigators, whether subjects have to be excluded from further treatment because of such reasons.
研究者
相似试验
进行中（未招募）
1 期
ong-term efficacy and safety evaluation of asenapine (10-20 mg/day) in subjects with schizophrenia or schizoaffective disorder, in a multicenter trial using olanzapine (10-20 mg/day) as a control.schizophrenia or schizoaffective disorderMedDRA version: 7.0 Level: HLGT Classification code 10039628EUCTR2004-001376-39-ESV Organon400
进行中（未招募）
1 期
ong-term efficacy and safety evaluation of asenapine (10-20 mg/day) in subjects with schizophrenia or schizoaffective disorder, in a multicenter trial using olanzapine (10-20 mg/day) as a control. - N/Aschizophrenia or schizoaffective disorderMedDRA version: 7.0 Level: HLGT Classification code 10039628EUCTR2004-001376-39-CZV Organon400
进行中（未招募）
1 期
ong-term Study to Assess the Safety and Effectiveness of NMRA-335140 in Participants with Major Depressive DisorderMajor Depressive DisorderCTIS2023-505892-56-00eumora Therapeutics Inc.870
已完成
不适用
A multicentre registry study to capture data with respect to CyPass clinical experience (CYCLE)GlaucomaEye DiseasesISRCTN74288501Transcend Medical, Inc.™ (USA)500
进行中（未招募）
1 期
ong-term study of BI695501 in patients with active rheumatoid arthritisMedDRA version: 18.1Level: PTClassification code 10039073Term: Rheumatoid arthritisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersRheumatoid arthritisEUCTR2015-002634-41-HUBoehringer Ingelheim International GmbH400